- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01104298
Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS
Randomized, Open, Multicenter, Prospective, Phase II Clinical Trial of Doxorubicin vs. Trabectedin Plus Doxorubicin in the First Line Treatment of Patients With Advanced Non Operable and/or Metastatic Soft Tissue Sarcomas
Study Overview
Detailed Description
The proposed investigation intends to explore if the combination of trabectedin and doxorubicin in the first line of treatment of advanced sarcomas obtains better results than doxorubicin monotherapy.
This proposal arises from the need to bring to the first line of treatment of advanced STS agents that have shown activity in second line. The goal is to improve available standard treatments. Tumors in patients not previously exposed to chemotherapy have not been selected in their biological behavior and they are the best scenario to test antitumor activity of a new anticancer drug.
The combination of drugs with different mechanisms of action may be a clear advantage to obtain better results and potential synergy. On the other hand, the toxicity profiles of both study drugs are different and worsening or summative of adverse effects is not expected.
The purpose of this study is to determine the efficacy of the combination of trabectedin and doxorubicin in comparison with doxorubicin alone in patients with advanced non operable and/or metastatic Soft Tissue Sarcomas (STS).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Badalona, Spain
- Ico Badalona
-
Barcelona, Spain
- H. Clinic Barcelona
-
Barcelona, Spain
- H. Sant Pau
-
Castellón, Spain
- H. Provincial Castellón
-
Girona, Spain
- Ico Girona
-
Lugo, Spain
- H. Xeral Cíes
-
Madrid, Spain
- H.U. Gregorio Maranon
-
Madrid, Spain
- Clinica Puerta Hierro
-
Madrid, Spain
- H. Clínico. San Carlos
-
Madrid, Spain
- H. U. La Paz
-
Madrid, Spain
- H.U. Ramón y Cajal
-
Málaga, Spain
- H.U. Clinico de Malaga
-
Navarra, Spain
- H. de Navarra
-
Oviedo, Spain
- H. C. Asturias
-
Palma de Mallorca, Spain
- H. Son Dureta
-
Santa Cruz de Tenerife, Spain
- H. Univ. Canarias
-
Sevilla, Spain
- H.U. Virgen del Rocio
-
Valencia, Spain
- Instituto Valenciano de Oncologia
-
Zaragoza, Spain
- H. Miguel Servet
-
-
Barcelona
-
L'Hospitalet, Barcelona, Spain
- ICO Hospitalet
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient must sign voluntarily the informed consent from before any study test is conducted that is not part of routine patient care, with the knowledge that he/she can abandon the study at any time without this affecting his/her previous care.
- Aged between 18 and 70.
- Pathological diagnosis of non operable and/or metastatic soft tissue sarcoma.
The following histological subtypes can be included:
- Undifferentiated pleomorphic sarcoma (previously,malignant fibrous istiocytoma)
- Leiomyosarcoma
- Angiosarcoma
- Liposarcoma
- Synovial sarcoma
- Fibrosarcoma
- Hemangiopericytoma
- Neurofibrosarcoma
- Mixofibrosarcoma
- Unclassified sarcoma
- Measurable disease, according to RECIST criteria
- Performance status 0-2 Eastern Cooperative Oncology Group(ECOG).
- Adequate bone marrow function (hemoglobin > 10 g/dL, leukocytes ≥ 3.000/mm3, neutrophils ≥1.500/mm3, platelets ≥ 100.000/mm3). Patients with plasma creatinine ≤ 1,6 mg/dL, transaminases ≤2.5 times the upper limit of normal (ULN), total bilirubin ≤ upper limit of normal (ULN), CPK ≤ 2.5 times upper limit of normal (ULN), alkaline phosphatase ≤ 2.5 times the upper limit of normal (ULN) are acceptable. If the increase of alkaline phosphatase is > 2.5 times the upper limit of normal (ULN), then the alkaline phosphatase liver fraction and/or 5' nucleotidase and/or GGT must be ≤ upper limit of normal (ULN).
- Men or women of child bearing potential should be using an effective method of contraception before entry into the study and throughout the same and for 6 months after ending the study. Women of childbearing potential must have a negative urine pregnancy test before study entry.
- Normal cardiac function with a Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram or Multiple Uptake Gated Acquisition Scan (MUGA).
Exclusion Criteria:
- Previous chemotherapy treatment.
- Previous radiotherapy involving the only localization(s) of measurable tumoral disease.
- Performance status> 2 Eastern Cooperative Oncology Group(ECOG).
- Central Nervous System (CNS) metastases.
- Plasma bilirubin > upper limit of normal(ULN).
- Creatinine > 1.6 mg/dL.
- History of other neoplastic disease with the exception of basalioma or in situ cervical cancer adequately treated.
- Significant cardiovascular disease (for example, dyspnea > 2 NYHA)
- Significant systemic diseases grade 3 or higher on the NCI-CTC version 3.0 scale, that limit patient availability, or according to investigator judgment may contribute significantly to treatment toxicity.
- Uncontrolled bacterial, mycotic or viral infections.
- Women who are pregnant or breast-feeding
- Psychological, familial, social or geographic circumstances that limit the patient's ability to comply with the protocol or informed consent.
- Patients participating in another clinical trial or receiving any other investigational product.
- Patients who had participated in another clinical trial and/or had received any other investigational product in the last 30 days prior to inclusion.
The following histologic subtypes are excluded:
- Rhabdomyosarcoma
- Ewing's family of tumors
- Desmoplastic small round cell tumor
- Clear cell sarcoma
- Alveolar sarcoma
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm A
Classic Doxorubicin (Adriamycin - Doxorubicin hydrochloride) Presentation: Solution with 10, 20, or 50 mg Doxorubicin Hydrochloride. Excipients: hydrochloric acid and sodium chloride 0.9%, q.s. 25 ml. Pharmaceutical form: concentrate for solution for infusion. Route of administration: Intravenous |
A maximum of 6 cycles every 3 weeks of doxorubicin monotherapy 75 mg/square meter will be given in the absence of progression or not acceptable toxicity.
Other Names:
|
Experimental: Arm B
Trabectedin Presentation: vials with trabectedin 1 mg and sucrose 400 mg. Pharmaceutical form: A white or whitish lyophilized powder as concentrate for solution for injection. Route of administration: for intravenous use after reconstitution and further dilution. Classic Doxorubicin (Adriamycin - Doxorubicin hydrochloride) Presentation: Solution with 10, 20, or 50 mg Doxorubicin Hydrochloride. Excipients: hydrochloric acid and sodium chloride 0.9%, q.s. 25 ml. Pharmaceutical form: concentrate for solution for infusion. Route of administration: Intravenous |
A maximum of 6 cycles every 3 weeks of the combination (Trabectedin 1,1 mg/square meter + doxorubicin 60 mg/square meter) will be given in the absence of progression or not acceptable toxicity.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the efficacy of the combination of trabectedin and doxorubicin in comparison with doxorubicin alone in patients with advanced non operable and/or metastatic Soft Tissue Sarcomas (STS)
Time Frame: 2012
|
To determine the efficacy of the combination of trabectedin and doxorubicin in comparison with doxorubicin alone in patients with advanced non operable and/or metastatic Soft Tissue Sarcomas (STS).
To this end, progression free survival will be compared between both groups of treatment.
|
2012
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine activity by means of RECIST objective responses in both study arms, trabectedin/doxorubicin combination and the control arm.
Time Frame: 2012
|
To determine activity by means of RECIST objective responses in both study arms, trabectedin/doxorubicin combination and the control arm.
|
2012
|
To determine the tumor control (response rates plus stabilizations) in both arms of treatment.
Time Frame: 2012
|
To determine the tumor control (response rates plus stabilizations) in both arms of treatment.
|
2012
|
Overall survival.
Time Frame: 2012
|
Overall survival.
|
2012
|
To determine activity by tissue changes applying the Choi criteria to Soft Tissue Sarcomas (STS)(see radiological review sub study).
Time Frame: 2012
|
To determine activity by tissue changes applying the Choi criteria to Soft Tissue Sarcomas (STS)(see radiological review sub study).
|
2012
|
To determine toxicity of trabectedin/doxorubicin combination and the control arm.
Time Frame: 2012
|
To determine toxicity of trabectedin/doxorubicin combination and the control arm.
|
2012
|
To determine protein and mRNA expression of genes possibly involved in a potential profile of more favorable response or resistance to study drugs and to analyze the prognostic impact of them on predefined efficacy parameters.
Time Frame: 2012
|
To determine protein and mRNA expression of genes possibly involved in a potential profile of more favorable response or resistance to study drugs and to analyze the prognostic impact of them on predefined efficacy parameters.
|
2012
|
To evaluate genomic instability, as well as protein expression that could influence response/resistance to the study drugs and make a correlation with efficacy endpoints.
Time Frame: 2012
|
To evaluate genomic instability, as well as protein expression that could influence response/resistance to the study drugs and make a correlation with efficacy endpoints.
|
2012
|
Collaborators and Investigators
Investigators
- Principal Investigator: Javier Martin Broto, PhM, GEIS
- Principal Investigator: Andres Poveda, Ph.M., GEIS
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Sarcoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Doxorubicin
- Trabectedin
Other Study ID Numbers
- GEIS-20
- 2008-008922-55 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcoma
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedUterine Corpus Leiomyosarcoma | Stage IIA Uterine Sarcoma | Stage IIB Uterine Sarcoma | Stage IIIA Uterine Sarcoma | Stage IIIB Uterine Sarcoma | Stage IIIC Uterine Sarcoma | Stage IVA Uterine Sarcoma | Stage IVB Uterine Sarcoma | Stage IA Uterine Sarcoma | Stage IB Uterine Sarcoma | Stage IC Uterine SarcomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedBone Sarcoma | Retroperitoneal Sarcoma | Adult Soft Tissue SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part SarcomaUnited States
-
Mohammed M MilhemGenentech, Inc.CompletedSarcoma | Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)CompletedRhabdomyosarcoma | Synovial Sarcoma | Ewing's Sarcoma | MPNST | High-risk SarcomaUnited States
-
Epizyme, Inc.RecruitingAdvanced Soft-tissue Sarcoma | Advanced Epithelioid SarcomaUnited States, Taiwan, Canada, United Kingdom
-
Brown UniversityActuate Therapeutics Inc.WithdrawnSoft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma of Bone | Leiomyosarcoma | High Grade Sarcoma | Liposarcoma | Rhabdomyosarcoma | Angiosarcoma | Bone Sarcoma | Synovial Sarcoma | Undifferentiated Pleomorphic Sarcoma | Myxofibrosarcoma | Spindle Cell SarcomaUnited States
-
Advenchen Laboratories, LLCActive, not recruitingLeiomyosarcoma | Synovial Sarcoma | Alveolar Soft Part Sarcoma | Soft-Tissue SarcomaUnited States, United Kingdom, Spain, China, Italy
-
Centre Oscar LambretFrench Sarcoma Group; Study Group of Bone TumorsCompletedSoft Tissue Sarcoma | Uterine SarcomaFrance
Clinical Trials on Doxorubicin
-
Azaya Therapeutics, Inc.UnknownCancer | Ovarian Cancer | Ovarian Epithelial Cancer Recurrent | Malignant Female Reproductive System Neoplasm | Ovarian TumorCanada, United States
-
National Cancer Institute (NCI)CompletedDS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Stage IV Breast Cancer AJCC...United States
-
OnxeoCompletedCarcinoma, HepatocellularItaly, Spain, United States, Belgium, Austria, France, Egypt, Germany, Hungary, Turkey, Lebanon
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Completed
-
Sohag UniversityActive, not recruiting
-
AEterna ZentarisCompletedEndometrial CancerUnited States, Spain, Canada, Ireland, Norway, Austria, Denmark, Israel, United Kingdom, Belgium, Finland, Romania, Czechia, Italy, Poland, Germany, Netherlands, Belarus, Bosnia and Herzegovina, Bulgaria, Russian Federation, Ukraine
-
SOLTI Breast Cancer Research GroupCompleted
-
Falo, Louis, MDActive, not recruitingCutaneous T Cell LymphomaUnited States
-
Boston Scientific CorporationBiocompatibles UK LtdCompletedPrimary Liver CancerAustria, Switzerland, France, Germany